2Orekhovich Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, ul. Pogodinskaya 10/8, 119121 Moscow, Russia; fax: +7 (499) 245-0857; E-mail: email@example.com
* To whom correspondence should be addressed.
Received October 16, 2013; Revision received December 15, 2013
New potential inhibitors of 5-lipoxygenase (5-LOX) based on the structure of 2-(3-benzoylphenyl)propanoic acid (an active component of the nonsteroidal antiinflammatory drug Ketoprofen) were designed using the SARD-21 program. The docking of these compounds in the active site of 5-LOX suggested that seven compounds can interact with this enzyme. Two of them can also be dual inhibitors of 5-LOX and two isoforms of cyclooxygenase.
KEY WORDS: molecular design, molecular docking, 5-lipoxygenase, cyclooxygenase isoforms